My watch list  


Systematic (IUPAC) name
CAS number 29767-20-2
ATC code L01CB02
PubChem 34698
DrugBank APRD00649
Chemical data
Formula C32H32O13S 
Mol. mass 656.655 g/mol
Pharmacokinetic data
Bioavailability n/a
Protein binding >99%
Metabolism Hepatic (CYP2C19-mediated)
Half life 5 hours
Excretion Renal and fecal
Therapeutic considerations
Pregnancy cat.


Legal status


Routes Intravenous

Teniposide (Vumon®, VM-26) is a chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia. It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body. Common side effects include nausea, vomiting, diarrhea, and thinned or brittle hair.

The medication is injected though a vein and burns if it leaks under the skin. It is sometimes used in combination with other anticancer drugs.

A major problem with teniposide is the lowered count of white blood cells 1-2 weeks after treatment. Though they should return to normal after 3-4 weeks, the decreased count puts a user at a risk of infection. The same also occurs for platelets.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Teniposide". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE